Seattle Genetics Inc. (SGEN) is in the Pharma Industry

• Sort by
• View by Content Type
• View Related Content by Tag

• My Model Biotech Picks: What's Hot and What's Not

  A. Reza Saadat submits: Analyzing the performance of my previous picks is by far my favorite part of writing this blog. It has on many occasions allowed be to learn from my mistakes.I have moved the numbers to Google docs so that they are easier to read. Here is...

  External links 2008-08-13

  Tags: Biotech, Alnylam Pharmaceuticals Inc., Amgen Inc., Amylin Pharmaceuticals Inc., Celgene Corp., Rigel Pharmaceuticals Inc., Seattle Genetics Inc.

• Genentech?s New ADC Platform Has Much Potential, but Is Yet to Be Tested on Humans

  Ohad Hammer submits: On June 18th, Seattle Genetics SGEN announced it had received a milestone payment from Genentech DNA after the latter filed an IND Investigational New Drug application for an antibody-drug conjugate [ADC] powered by Seattle Genetics’ technology.  Intriguingly, there was no additional data about the new agent, nor...

  External links 2008-08-06

  Tags: Biotech, Healthcare, Genentech Inc., ImmunoGen Inc., Seattle Genetics Inc.

• Seattle Genetics Inc. Q2 2008 Earnings Call Transcript

  Question-and-Answer SessionOperator Thank you. We will now begin the Question and Answer session. Operator Instructions. Our first question comes from the line of Mark Monane from Needham. Please go ahead. Mark Monane - Needham Good afternoon and greetings from New York City. A very hot day in New York...

  Earnings calls 2008-07-22

  Tags: Seattle Genetics Inc.

• Seattle Genetics Inc. Q1 2008 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator instructions Our first question comes from the line of Glenn from Needham & Company. Glenn - Needham & Company Hi, good afternoon. Congratulations on progress with all of your programs. I have a question about SGN-33 in the AML program, in the elderly AML...

  Earnings calls 2008-04-24

  Tags: Seattle Genetics Inc.

• Seattle Genetics Inc. Q4 2007 Earnings Call Transcript

  Question-and-Answer SessionOperator Thank you sir, ladies and gentlemen at this time we will begin the question and answer session. Operator Instructions One moment please for the first question. Our first question will from the line of Richard Smith with J.P. Morgan. Please go ahead. ...

  Earnings calls 2008-02-19

  Tags: Seattle Genetics Inc.

• Seattle Genetics Q3 2007 Earnings Call Transcript

  Question-and-Answer SessionOperator Thank you. Ladies and gentlemen, we will conduct the question-and-answer session Operator Instructions. Our first question comes from the line of George Farmer with Wachovia Securities. George Farmer - Wachovia Securities Hi. Thanks for taking my question. Clay, can you talk about what you saw in Phase...

  Earnings calls 2007-10-26

  Tags: Seattle Genetics Inc.

Additional Resources

• Seattle Genetics to Present at Upcoming Investor Conferences

  BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics, will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor...

  Articles 2008-08-27

• Seattle Genetics Initiates SGN-70 Phase I Clinical Trial

  BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase I clinical trial of SGN-70, a humanized monoclonal antibody targeting CD70 that is being developed as an investigational therapy for autoimmune diseases. The trial will assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy...

  Articles 2008-07-31

• Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Daiichi Sankyo

  BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into an exclusive, worldwide collaboration agreement with Daiichi Sankyo Co., Ltd. (TSE:4568) for the development of antibody-drug conjugates ADCs targeting a single antigen found on multiple types of solid tumors. Under the...

  Articles 2008-07-08

• VLST Corporation Appoints Internationally Recognized Researcher Paul J. Carter, Ph.D. as Chief Scientific Officer

  SEATTLE -- VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, today announced that Paul J. Carter, Ph.D., a 20-year biotechnology research veteran, will join the Company as chief scientific officer and senior vice president of research and development....

  Articles 2008-07-02

• Weyerhaeuser Wins Best of Show at NIRI Seattle's Investor Communications Awards Gala

  SEATTLE -- The Seattle Chapter of the National Investor Relations Institute NIRI announced today that Weyerhaeuser's 2007 annual report won "Best of Show" at the 2008 Investor Communications Awards Gala held June 26. Seattle Genetics won Best in Show among Biopharma/Healthcare entries, a new category this year....

  Articles 2008-06-27

• Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing

  BOTHELL, Wash. -- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate ADC collaboration with Genentech, Inc. The milestone was triggered by Genentech's filing of an Investigational New Drug IND application with the U.S. Food and Drug Administration FDA for...

  Articles 2008-06-18

• Pacific Biometrics, Inc. Ranked 8th in a Survey of Fastest-Growing Public Companies in Washington State

  Pacific Biometrics, Inc. (OTCBB: PBME) ("PBI"),a leading provider of specialized central laboratory and contract researchservices, has been identified as the 8th fastest-growing public company inWashington state by the Puget Sound Business Journal. In its May 23-29,2008 issue (vol. 29, no. 5), the Puget Sound Business Journal published...

  Articles 2008-06-17

• Seattle Genetics Announces SGN-35 Plenary Presentation at International Conference on Malignant Lymphoma

  SEATTLE -- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that SGN-35 will be highlighted in an oral presentation during a plenary session on Saturday, June 7, 2008 at the International Conference on Malignant Lymphoma ICML being held in Lugano, Switzerland. In a phase I dose-escalation...

  Articles 2008-06-06

• Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma

  SEATTLE -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced final data from the phase I clinical trial of SGN-40 in patients with relapsed or refractory non-Hodgkin lymphoma. SGN-40 is a humanized monoclonal antibody being developed under a worldwide collaboration agreement with Genentech, Inc. Multiple objective responses were achieved...

  Articles 2008-06-05

• Seattle Genetics to Present at Upcoming Investor Conferences

  BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section. Needham & Company 7th Annual Biotechnology and Medical...

  Articles 2008-06-04

• Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma

  - 81% of evaluable patients achieved reductions in tumor volume - SEATTLE -- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced positive data from a phase I clinical trial of SGN-35, an antibody-drug conjugate ADC, demonstrating multiple objective responses at well-tolerated doses in patients with Hodgkin lymphoma and other...

  Articles 2008-06-03

• Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma

  BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that its collaborator, Genentech, Inc., has initiated a phase Ib clinical trial of SGN-40 in combination with Velcade[R] bortezomib for patients with relapsed or refractory multiple myeloma. This is the sixth ongoing clinical trial to evaluate SGN-40 either as a single...

  Articles 2008-06-02

• SEATTLE GENETICS HAS FIRST QTR 2008 NET LOSS OF $17.I MIL.(Financial report)

  Seattle Genetics, Inc. (Nasdaq:SGEN) Bothell, Wash., has reported financial results for the first quarter of 2008. "We continue to advance and expand our robust product pipeline, including recent trial initiations with each of our clinical programs, SGN-40, SGN-33 and SGN-35," said Clay B....

  Articles 2008-06-01

• Seattle Genetics Announces Upcoming SGN-35 Presentation at the American Society of Clinical Oncology Annual Meeting

  BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that SGN-35 phase I clinical data will be presented during a poster discussion session at the 44th American Society of Clinical Oncology ASCO Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in...

  Articles 2008-05-16